Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Forestviewon Apr 12, 2021 3:15pm
468 Views
Post# 32978941

Email from Dan

Email from DanSome of you may remember, I emailed Dan a week ago this email:

What's the timing on the ATE/AH amalgamation to be completed?  Right now, based on the market cap and share price, looks like there are 45.5million shares outstanding, so I suspect the process has started. 
 
It's frustrating to see a good news report about the IND come out last week only to have no reaction (in fact, share price dropped), so I'm not sure if the market is waiting for this amalgamation to be completed.
 
I'm just waiting for this stock to take off, or even just rise sustainably, and it seems to be held back for whatever reason.  I'd appreciate your thoughts.  

He just responded with this...

Thanks for your note... the amalgamation is a priority for us and we look forward to providing an update on the process and timing shortly. The share count figure you are referencing reflects the new issuance of shares from our recent financing. I agree with you regarding the lack of response to the IND announcement but of course we are excited to have FDA clearance to commence human trials in the US. It’s an important milestone that also strengthens our hand in discussions with potential partners as it further de-risks our regulatory path. Thanks as always for your continued support.

<< Previous
Bullboard Posts
Next >>